Gupta, V., Yacoub, A., Fazal, S., Miller, C., Verstovsek, S., Mesa, R., … Talpaz, M. (2020). Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (Vol. 20, pp. S331–S332).

Gupta, Vikas, Abdulraheem Yacoub, Salman Fazal, Carole Miller, Srdan Verstovsek, Ruben Mesa, Claire Harrison, et al. “Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib.” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 20:S331–32, 2020.

Gupta V, Yacoub A, Fazal S, Miller C, Verstovsek S, Mesa R, et al. Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2020. p. S331–2.

Gupta, Vikas, et al. “Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib.” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 20, 2020, pp. S331–32.

Gupta V, Yacoub A, Fazal S, Miller C, Verstovsek S, Mesa R, Harrison C, Barosi G, Kiladjian J-J, Mattison R, Rein L, Reeves B, Oh S, Parameswaran V, Deeg J, Rose S, Chia V, Wang T, Talpaz M. Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2020. p. S331–S332.